Sotrovimab market report points to faster growth in Asia-Pacific

The Business Research Company says the global sotrovimab, or Xevudy, market will be shaped by COVID-19 infection rates, healthcare spending and demand for variant-resistant therapies through 2035. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Sotrovimab remains part of the antiviral therapeutics market as COVID-19 care shifts toward early treatment, outpatient delivery and pandemic preparedness. - The market outlook signals where demand may hold up as health systems continue to plan for future variants and high-risk patients.

What happened: - The Business Research Company released its Sotrovimab or Xevudy Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report covers market size, trends and forecasts for sotrovimab, marketed as Xevudy, through 2035. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Sotrovimab is a monoclonal antibody designed to target the spike protein of SARS-CoV-2 and help prevent the virus from infecting human cells. - The treatment is primarily used for mild to moderate COVID-19 in patients at elevated risk of severe illness. - Historical market growth was driven by emergency authorizations for COVID-19 monoclonal antibodies, early-pandemic hospitalization risk, rapid rollout of antibody therapies, government procurement of antiviral drugs and expansion of infusion infrastructure. - Forecast growth is expected to come from variant-resistant antibody therapies, greater pandemic preparedness, higher investment in antiviral biologics, wider outpatient infusion services and integration of monoclonal antibodies into routine care protocols. - Key trends in the report include broader monoclonal antibody use, earlier viral intervention, more targeted antiviral treatments, stronger protection for high-risk patients and faster development of therapies for future pandemics. - The report says rising COVID-19 infections are a major driver of market expansion. - The report links continued demand to emerging variants, waning immunity, relaxation of safety measures, seasonal indoor gatherings and uneven vaccine distribution. - The report cites UK Office for National Statistics data from March 2023 showing 1.9 million people in the UK, or 2.9% of the population, reported COVID-19, with many experiencing symptoms lasting more than a year. - Rising healthcare spending is another driver cited in the report. - The report cites UK Office for National Statistics data showing total healthcare expenditure rose 5.6% nominally from 2022 to 2023, compared with 0.9% growth in the prior year. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - The report also includes Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional breakdown. - The source includes links for a free sample of the report and the full market report.

Between the lines: - The report frames sotrovimab as a market tied less to broad pandemic emergency use and more to targeted treatment for vulnerable patients. - The emphasis on outpatient infusion, routine care protocols and variant resistance suggests the commercial case now depends on how health systems adapt to COVID-19 as an ongoing disease rather than a crisis-only response.

What's next: - The report expects continued market growth through 2035 if infection pressure, healthcare investment and demand for early antiviral treatment remain elevated. - Asia-Pacific’s projected growth could shift more attention to distribution, access and treatment infrastructure in the region. - The company is offering report access and expert contact details for follow-up inquiries.